176 related articles for article (PubMed ID: 20361170)
1. Drug treatments for skin disease introduced in 2009.
Skin Therapy Lett; 2010 Feb; 15(2):6-7. PubMed ID: 20361170
[No Abstract] [Full Text] [Related]
2. Drug treatments for skin disease introduced in 2006.
Skin Therapy Lett; 2007 May; 12(4):4-7. PubMed ID: 17551663
[TBL] [Abstract][Full Text] [Related]
3. Drug treatments for skin disease introduced in 2007.
Skin Therapy Lett; 2008 Mar; 13(2):7-9. PubMed ID: 18373042
[TBL] [Abstract][Full Text] [Related]
4. Drug treatments for skin disease introduced in 2001.
Skin Therapy Lett; 2002 Feb; 7(2):6-7. PubMed ID: 12007014
[No Abstract] [Full Text] [Related]
5. Drug treatments and labeling changes for skin disease introduced in 2002.
Skin Therapy Lett; 2003 Feb; 8(2):5-7. PubMed ID: 12728283
[No Abstract] [Full Text] [Related]
6. Drug treatments for skin disease introduced in 2003.
Skin Therapy Lett; 2004 Apr; 9(4):3-4. PubMed ID: 15146263
[No Abstract] [Full Text] [Related]
7. Drug treatments for skin disease introduced in 2000.
Skin Therapy Lett; 2001 Feb; 6(5):4-6. PubMed ID: 11242138
[No Abstract] [Full Text] [Related]
8. Advances in dermatopharmacology--strength and weakness of recently of approved drugs (I).
Chang YC; Maibach HI
Int J Clin Pharmacol Ther; 1997 May; 35(5):188-94. PubMed ID: 9174873
[No Abstract] [Full Text] [Related]
9. Generic drugs--safe, effective, and affordable.
Peters JR; Hixon DR; Conner DP; Davit BM; Catterson DM; Parise CM
Dermatol Ther; 2009; 22(3):229-40. PubMed ID: 19453347
[TBL] [Abstract][Full Text] [Related]
10. Dapsone: unapproved uses or indications.
Wolf R; Tüzün B; Tüzün Y
Clin Dermatol; 2000; 18(1):37-53. PubMed ID: 10701085
[No Abstract] [Full Text] [Related]
11. [Dihydroxyacetone and its use in dermatology and cosmetics. (Review)].
Rudowska I
Z Haut Geschlechtskr; 1967 Nov; 42(21):649-53. PubMed ID: 5596906
[No Abstract] [Full Text] [Related]
12. Off-label uses of biologic agents in dermatology: a 2006 update.
Kerns MJ; Graves JE; Smith DI; Heffernan MP
Semin Cutan Med Surg; 2006 Dec; 25(4):226-40. PubMed ID: 17174843
[TBL] [Abstract][Full Text] [Related]
13. Skin Pharmacology Society. 5th annual symposium. May 27-28, 1988, Paris. Abstracts.
Skin Pharmacol; 1988; 1(1):38-75. PubMed ID: 3272750
[No Abstract] [Full Text] [Related]
14. Biosimilars in dermatology: starting with infliximab.
Puig L
Actas Dermosifiliogr; 2013 Apr; 104(3):175-80. PubMed ID: 23218608
[No Abstract] [Full Text] [Related]
15. Skin Pharmacology Society. 6th annual meeting. September 1-2, 1989, New York. Abstracts.
Skin Pharmacol; 1989; 2(1):41-60. PubMed ID: 2627413
[No Abstract] [Full Text] [Related]
16. Topical retinoids and cutaneous biology.
Craven NM; Griffiths CE
Clin Exp Dermatol; 1996 Jan; 21(1):1-10. PubMed ID: 8689759
[No Abstract] [Full Text] [Related]
17. [Local treatments in dermatology].
Moureaux P
Allerg Immunol (Paris); 1995 Jun; 27(6):200-5. PubMed ID: 7626195
[No Abstract] [Full Text] [Related]
18. Repurposing of drugs for dermatologic applications: five key medications.
Adler BL; Friedman AJ
J Drugs Dermatol; 2014 Nov; 13(11):1413-6. PubMed ID: 25607712
[No Abstract] [Full Text] [Related]
19. [Dermatology].
Jung EG
Arzneimittelforschung; 1997 Oct; 47(10):1174-6. PubMed ID: 9454561
[TBL] [Abstract][Full Text] [Related]
20. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
Weaver J; Grenade LL; Kwon H; Avigan M
Dermatol Ther; 2009; 22(3):204-15. PubMed ID: 19453344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
